Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.

Aim: To compare the efficacy and safety of biological agents for the treatment of active ulcerative colitis (UC).

Methods: PubMed, MEDLINE, EMBASE and the Cochrane library were searched to screen relevant articles from January 1996 to August 2014. The mixed treatment comparison meta-analysis within a Bayesian framework was performed using WinBUGS14 software.